Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by...
Biotech company Clearmind Medicine has announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq.
Global investment firm Psych Capital has announced the completion of its 100% acquisition of life science company Short Wave Pharma.
Drug Science has launched a new consultancy arm with an emphasis on the emerging cannabis and psychedelic medicine markets.
Awakn Life Sciences has completed the sale of Awakn London Limited Ltd.,
A new Ethics Council was launched at the Inaugural Summit of The World’s Leaders in Psychedelics that will work to guide industry standards and best practices.
After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders who are looking to transform the...
Optimi Health has entered into a long-term distribution agreement with Mind Medicine Australia to supply its MDMA formulation, OPTI-MHCL, and GMP psilocybin capsules.
Canadian biotechnology company, PharmAla Biotech, has submitted its pre-IND data meeting package to the US Food and Drug Administration (FDA) for its novel MDMA analogue.
Beckley Psytech has entered into a definitive agreement to acquire clinical-stage life science company, Eleusis Therapeutics Limited, in an all-equity transaction.
